| Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA (NCT05181735) | Groupe Francophone des Myelodysplasies | 2022-05-18 |
| A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure (NCT05285813) | M.D. Anderson Cancer Center | 2022-05-06 |
| GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG (NCT05153226) | DKMS gemeinnützige GmbH | 2022-03-02 |
| Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) (NCT05177211) | H. Lee Moffitt Cancer Center and Research Institute | 2022-03-01 |
| Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS (NCT04901416) | Coeptis Therapeutics | 2021-12-15 |
| Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS (NCT04749355) | BioSight Ltd. | 2021-11-14 |
| Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia (NCT05024877) | Peking Union Medical College Hospital | 2021-10-01 |
| APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) (NCT04638309) | Aprea Therapeutics | 2021-09-20 |
| Optical Genome Mapping in Hematological Malignancies (NCT05009537) | University Hospital, Brest | 2021-09-01 |
| Precision Therapy Versus Standard Therapy in AML and MDS in Elderly (NCT05025098) | University Hospital, Akershus | 2021-06-22 |
| Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS (NCT05175508) | The First Affiliated Hospital of Soochow University | 2021-05-01 |
| A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML (NCT04730258) | Treadwell Therapeutics, Inc | 2021-04-16 |
| Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients (NCT04806906) | University of Florence | 2021-03-24 |
| Prognostic Value of Serum Erythropoietin Level,Ferritin Level and Fibrinogen in Adult Low Risk MDS (NCT04573686) | Assiut University | 2021-01-01 |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS (NCT04358393) | Ascentage Pharma Group Inc. | 2020-12-04 |
| National Longitudinal Cohort of Hematological Diseases (NCT04645199) | Institute of Hematology & Blood Diseases Hospital, China | 2020-12-01 |
| Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (NCT04644016) | Memorial Sloan Kettering Cancer Center | 2020-11-20 |
| NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS (NCT04623944) | Nkarta, Inc. | 2020-09-21 |
| A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies (NCT04547049) | First Affiliated Hospital of Zhejiang University | 2020-09-01 |
| A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS (NCT04511975) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-08-24 |
| Haplo Peripheral Blood Sct In GVHD Prevention (NCT04473911) | Zachariah Michael DeFilipp | 2020-08-14 |
| BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) (NCT04187105) | University of Illinois at Chicago | 2020-01-27 |
| Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML (NCT07318662) | Guangdong Provincial People's Hospital | 2020-01-01 |
| CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure. (NCT04109690) | Yale University | 2019-12-30 |
| Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With Myelodysplasia (NCT04110925) | Sunnybrook Health Sciences Centre | 2019-09-01 |
| Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML (NCT04061239) | GWT-TUD GmbH | 2019-08-19 |
| CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS (NCT04017546) | Cyclacel Pharmaceuticals, Inc. | 2019-08-02 |
| Study on High-risk MDS Patients Based on RNA-seq Technology (NCT03903055) | Zhejiang Provincial Hospital of TCM | 2019-05-01 |
| Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT (NCT03336632) | Sichuan University | 2019-01-01 |
| Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies (NCT03680677) | Abramson Cancer Center at Penn Medicine | 2018-09-21 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies (NCT03465540) | Amgen | 2018-08-17 |
| Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS (NCT03459859) | Justin Watts, MD | 2018-05-21 |
| Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS (NCT03855371) | Ruijin Hospital | 2018-01-10 |
| Haploidentical Donor vs mMUD in Hematological Malignancies (NCT03275636) | DKMS gemeinnützige GmbH | 2018-01-01 |
| Ascorbic Acid Levels in MDS, AML, and CMML Patients (NCT03526666) | Van Andel Research Institute | 2017-11-01 |
| iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML (NCT03138395) | University of Florida | 2017-09-15 |
| CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia (NCT02995655) | Washington University School of Medicine | 2017-04-07 |
| Familial Investigations of Childhood Cancer Predisposition (NCT03050268) | St. Jude Children's Research Hospital | 2017-04-06 |
| A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders (NCT02985190) | Groupe Francophone des Myelodysplasies | 2017-01-26 |
| Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT (NCT02872662) | Nordic MDS Group | 2016-08-01 |
| Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk (NCT02757989) | Groupe Francophone des Myelodysplasies | 2016-05-31 |
| Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (NCT02562443) | Traws Pharma, Inc. | 2015-12-02 |
| A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations (NCT02418000) | Spirita Oncology, LLC | 2015-04-10 |
| Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source (NCT02167958) | Rafic Farah, MD | 2015-02-11 |
| A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients (NCT02323139) | Groupe Francophone des Myelodysplasies | 2015-02-10 |
| Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML (NCT02214407) | Groupe Francophone des Myelodysplasies | 2014-10-14 |
| Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation (NCT02226861) | National Heart, Lung, and Blood Institute (NHLBI) | 2014-08-26 |
| A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response (NCT02197676) | Groupe Francophone des Myelodysplasies | 2014-08-04 |
| Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies (NCT02193958) | Fujifilm Pharmaceuticals U.S.A., Inc. | 2014-07-01 |
| Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) (NCT02016781) | Medical College of Wisconsin | 2013-12-16 |
| Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA (NCT01993641) | Helsinn Healthcare SA | 2013-12-01 |
| Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion (NCT02053545) | Ann & Robert H Lurie Children's Hospital of Chicago | 2013-12-01 |
| Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (NCT01861106) | National Cancer Institute (NCI) | 2013-07-24 |
| A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS (NCT01718366) | Groupe Francophone des Myelodysplasies | 2013-02-01 |
| Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） (NCT01690507) | Chinese PLA General Hospital | 2012-11-01 |
| FLT-PET Imaging for MDS (NCT01535456) | University of Wisconsin, Madison | 2012-07-01 |
| Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (NCT01584531) | Traws Pharma, Inc. | 2012-05-01 |
| Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (NCT01362140) | Amgen | 2011-12-21 |
| A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome (NCT01497145) | Kyowa Kirin Co., Ltd. | 2011-12-01 |
| The Effect of Blood Transfusion on Endothelial Function (NCT02161042) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2011-08-01 |
| ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS (NCT01423175) | Hannover Medical School | 2011-07-01 |
| Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes (NCT01342692) | Assistance Publique - Hôpitaux de Paris | 2011-06-01 |
| SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) (NCT01261312) | Astex Pharmaceuticals, Inc. | 2011-01-04 |
| A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes (NCT01379274) | Rush University Medical Center | 2011-01-01 |
| Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts (NCT01241500) | Traws Pharma, Inc. | 2010-11-01 |
| Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies (NCT01204164) | Tragara Pharmaceuticals, Inc. | 2010-08-01 |
| Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS (NCT01133275) | H. Lee Moffitt Cancer Center and Research Institute | 2010-04-28 |
| Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) (NCT01019317) | M.D. Anderson Cancer Center | 2009-11-01 |
| Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML (NCT06267898) | European Society for Blood and Marrow Transplantation | 2009-11-01 |
| Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) (NCT00863148) | Nantes University Hospital | 2009-10-01 |
| Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders (NCT00973804) | National Cancer Institute (NCI) | 2009-08-25 |
| Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC (NCT00923364) | National Cancer Institute (NCI) | 2009-05-07 |
| Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) (NCT00887068) | M.D. Anderson Cancer Center | 2009-04-21 |
| STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders (NCT00858572) | Synta Pharmaceuticals Corp. | 2009-03-01 |
| Global Registry and Natural History Study for Mitochondrial Disorders (NCT05554835) | LMU Klinikum | 2009-02-01 |
| Umbilical Cord Blood Transplant for Hematological Malignancies (NCT00891592) | University of Pennsylvania | 2009-01-01 |
| Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy (NCT00796562) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2008-12-01 |
| Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI) (NCT00815568) | Samsung Medical Center | 2008-08-01 |
| Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (NCT00614523) | Amgen | 2008-07-21 |
| A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients (NCT00699842) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2008-07-01 |
| Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders (NCT00687414) | Corewell Health West | 2008-04-01 |
| Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant (NCT00684008) | Cytheris, Inc. | 2008-03-01 |
| Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 (NCT00761449) | Nordic MDS Group | 2007-10-01 |
| Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes (NCT00493571) | M.D. Anderson Cancer Center | 2007-08-01 |
| Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft (NCT00814983) | Duke University | 2007-07-01 |
| Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) (NCT00472290) | Amgen | 2007-04-01 |
| A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status (NCT00462761) | Daiichi Sankyo | 2007-01-01 |
| Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents (NCT00321711) | Amgen | 2006-10-01 |
| Velcade in Myelodysplastic Syndrome - Pilot Study (NCT00440076) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2006-08-01 |
| Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS) (NCT00303472) | Amgen | 2006-02-01 |
| Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases (NCT00309842) | Masonic Cancer Center, University of Minnesota | 2005-07-28 |
| Stem Cell Transplant for Hematological Malignancy (NCT00176930) | Masonic Cancer Center, University of Minnesota | 2001-10-01 |
| Allogeneic Transplantation From Related Haploidentical Donors (NCT00185692) | Stanford University | 2000-08-01 |
| Stem Cell Transplantation for Hematological Malignancies (NCT00176839) | Masonic Cancer Center, University of Minnesota | 2000-06-07 |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders (NCT00636909) | Beth Israel Deaconess Medical Center | 1999-07-01 |
| Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant (NCT00530218) | City of Hope Medical Center | 1999-03-01 |
| Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia (NCT00167167) | Masonic Cancer Center, University of Minnesota | 1995-12-01 |